key: cord-0934082-vrbsbwgv
authors: Ambati, Aditya; Valentini, Davide; Montomoli, Emanuele; Lapini, Guilia; Biuso, Fabrizio; Wenschuh, Holger; Magalhaes, Isabelle; Maeurer, Markus
title: H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix® vaccination
date: 2015-04-15
journal: Immunology
DOI: 10.1111/imm.12448
sha: 96442d0caa3e7c730bd9794da6a25e07b278b4f2
doc_id: 934082
cord_uid: vrbsbwgv

A high content peptide microarray containing the entire influenza A virus [A/California/08/2009(H1N1)] proteome and haemagglutinin proteins from 12 other influenza A subtypes, including the haemagglutinin from the [A/South Carolina/1/1918(H1N1)] strain, was used to gauge serum IgG epitope signatures before and after Pandemrix® vaccination or H1N1 infection in a Swedish cohort during the pandemic influenza season 2009. A very narrow pattern of pandemic flu-specific IgG epitope recognition was observed in the serum from individuals who later contracted H1N1 infection. Moreover, the pandemic influenza infection generated IgG reactivity to two adjacent epitopes of the neuraminidase protein. The differential serum IgG recognition was focused on haemagglutinin 1 (H1) and restricted to classical antigenic sites (Cb) in both the vaccinated controls and individuals with flu infections. We further identified a novel epitope VEPGDKITFEATGNL on the Ca antigenic site (251–265) of the pandemic flu haemagglutinin, which was exclusively recognized in serum from individuals with previous vaccinations and never in serum from individuals with H1N1 infection (confirmed by RNA PCR analysis from nasal swabs). This epitope was mapped to the receptor-binding domain of the influenza haemagglutinin and could serve as a correlate of immune protection in the context of pandemic flu. The study shows that unbiased epitope mapping using peptide microarray technology leads to the identification of biologically and clinically relevant target structures. Most significantly an H1N1 infection induced a different footprint of IgG epitope recognition patterns compared with the pandemic H1N1 vaccine.

A high content peptide microarray containing the entire influenza A virus [A/California/08/2009(H1N1)] proteome and haemagglutinin proteins from 12 other influenza A subtypes, including the haemagglutinin from the [A/South Carolina/1/1918(H1N1)] strain, was used to gauge serum IgG epitope signatures before and after Pandemrix â vaccination or H1N1 infection in a Swedish cohort during the pandemic influenza season 2009. A very narrow pattern of pandemic flu-specific IgG epitope recognition was observed in the serum from individuals who later contracted H1N1 infection. Moreover, the pandemic influenza infection generated IgG reactivity to two adjacent epitopes of the neuraminidase protein. The differential serum IgG recognition was focused on haemagglutinin 1 (H1) and restricted to classical antigenic sites (Cb) in both the vaccinated controls and individuals with flu infections. We further identified a novel epitope VEPGDKITFEATGNL on the Ca antigenic site (251-265) of the pandemic flu haemagglutinin, which was exclusively recognized in serum from individuals with previous vaccinations and never in serum from individuals with H1N1 infection (confirmed by RNA PCR analysis from nasal swabs).

The influenza pandemic 2009, caused by novel triple reassorted swine origin influenza A virus H1N1, was first identified in the USA. [1] [2] [3] [4] The European Centre for Disease Control estimated that 1975 laboratory confirmed death cases were reported all over Europe in the first year. 5 The seasonal influenza vaccines, either adjuvanted or non-adjuvanted, exhibited no protective effect as measured by a haemagglutinin (HA) inhibition assay in young adults and children, although individuals born before 1950 showed protective serum IgG titres. 3, 6, 7 The lack of pre-existing neutralizing antibodies against the pandemic influenza virus increased the susceptibility in the general population. 8 Only 31% of B-cell epitopes were conserved in the pandemic (swine-origin influenza virus) strain compared with the seasonal variant flu strains; moreover, of the eight conserved epitopes, only a single epitope was from HA. 9 The HA ectodomain is a homotrimeric complex with four distinct antigenic sites with two polypeptide chains HA1 and HA2. Each homotrimer is comprised of a large globular head that binds to glycan receptors and a distal stem region. 10, 11 Haemagglutinin is the target of neutralizing antibodies in the context of pandemic influenza 2009 12 and often described as the immunogenicity-defining surface protein of influenza viruses. 11, 13, 14 Therefore, we mapped in this study the serum IgG epitope recognition profiles after a natural pandemic flu infection and Pandemrix â vaccination using a high content influenza peptide microarray. 15, 16 Serum antibody-based protein target identification (SEREX) has been used to successfully identify a number of biologically relevant targets in cancer [17] [18] [19] [20] and to show differences in the epitope recognition pattern in the course of HIV infection versus (gp120) HIV vaccination. 21 We choose a similar approach to define the epitope recognition pattern in serum using synthetic linear peptide stretches to define (i) the immune recognition pattern to segregate individuals at high risk of infection with influenza virus, (ii) differences in IgG recognition patterns induced by vaccination versus infection, and (iii) shared epitope recognition patterns comparing different HA proteins from influenza A strains, including the HA from the pandemic strain influenza A virus [A/South Carolina/1/1918(H1N1)]. Up to now, immunological differences between time-points (e.g. before/after flu vaccination) or between different patient groups were assayed by ELISA. 22 Using this method, only increase in titres or reactivity to different targets could be measured. However, recognition of recombinant proteins in ELISA usually represents recognition of 20-40 different epitopes (linear and conformational). Peptide array screening is a feasible way to map differences in humoral immune responses, though an important limitation may be the exclusion of conformational epitopes, as described in recent reports. 23, 24 The epitope-mapping analysis was possible in the current study using material from a prospective study, [25] [26] [27] in which 2000 individuals were followed before and after vaccination, or H1N1 infection.

The peptide arrays were custom manufactured by JPT (Berlin, Germany) and the manufacturing process based on SPOT synthesis has been described elsewhere. 28 These were used to assay the detailed flu epitope recognition pattern. Serum samples from 19 (age-and sexmatched) individuals vaccinated with the adjuvanted vaccine against pandemic H1N1 influenza (Pandemrix â ) were used as controls (see Fig. 1 ). The regional ethics committee in Stockholm (2009/1183-31) approved the study.

The serum was diluted 1 : 100 in 300 ll buffer (PBS 3% fetal calf serum 0Á5% Tween 80) (Sigma Aldrich, St Louis, MO) and incubated on microarrays for 16 hr in a humid chamber at + 4°C, the slides were then washed with buffer twice and sterile distilled water thrice, followed by secondary incubation with 300 ll diluted (1 : 500) monoclonal Cy5 â -labelled mouse anti-human IgG antibody [Cat no: 9042-15 lot: C4505-X595J (0Á1 mg/ml) (Southern Biotech, Birmingham, AL)] for an hour at room temperature and then washed as before. The slides were spun dry in a slide centrifuge (DJB Labcare, Newport Pagnell, UK) and scanned at 635 nm using an Axon 4000B scanner (Molecular Devices, Sunnyvale, CA). Image analysis was performed using the circular feature alignment of the GENEPIX Pro 7.0 software (Molecular Devices) and Genepix Array List (GAL) files (supplied by JPT, Berlin, Germany).

Each slide was analysed by using GENEPIX 7.0 image analysis software (Molecular Devices) and the GAL file that contained the peptide information for each spot as supplied by the manufacturer (JPT, Berlin, Germany). The detectable spots that are not internally uniform are flagged as 'bad' (i.e. unreliable). This is efficiently estimated by the following criterion (described in detail elsewhere 16 ).

ð½F635

which identifies the spots with a mean foreground value different from the spots exhibiting median fluorescence intensity values. The spots were visually inspected after flagging and the results were saved separately for each subarray. The positive control spots in each sub-array were selected after careful screening, as described previously. 29 Two paired strategies were adopted in this context: differential recognition of epitopes, i.e. peptides exhibiting statistically different recognition from immunoglobulin present in the test group compared with the control group, (strong recognition in one group versus weak or no recognition in the other group), as well as 'exclusive recognition' of peptide targets that are recognized above a defined threshold for detection in serum from a test group but never in a control group (or vice versa). 15, 16, 29, 30 The epitope mapping on the crystal structure of the 2009 H1N1 influenza virus HA (PDB ID-3LZG) 31 and HA receptor-binding domain (PDB ID -3MLH) 32 were performed using the protein databank Jmol, an open-source Java viewer for chemical structures using a three-dimensional application (http://www.jmol.org). 33 Monospecific antibody production and H1N1 neutralization assay A polyclonal monospecific rabbit antibody specific to VEPGDKITFEATGNL was prepared by Genscript (Piscataway, NJ) and the specificity was verified by an indirect ELISA (data not shown). The peptide-specific polyclonal reagents were prepared in three different rabbits and affinity-purified using the immobilized VE-PGDKITFEATGNL peptide attached to a linker. The affinity-purified reagent did not show cross-reactivity to other, non-relevant peptide targets. The three antibody reagents were individually used in neutralization experiments.

The molecular epidemiology laboratory, at the University of Siena, performed the virus neutralization assay using the cytopathic effect as the readout against the influenza virus H1N1 A/California/7/2009 as previously described. 34 The affinity-purified monospecific antibody (heat-inactivated for 30 min at 56°C) was serial twofold diluted starting from 10 À1 up to 10 À10 dilutions and incubated at 37°C for 1 hr with 100 TCID 50 /50 ll of influenza live virus (in equal volume/well) H1N1 A/California/7/2009. The incubation of monospecific antibody and virus allows the neutralization of virus by specific antibodies. The mixture was then added to 90% confluent monolayered MDCK (Madin Darbin Canine Kidney) susceptible cells in 96-well flat-bottomed microtitre plates. These plates were incubated at 37°C in 0Á5% CO 2 for 5 days, to allow infection of the cell substrate in case live virus was not neutralized by serum antibodies. The cytopathic effect was monitored every day and at the end of the incubation period, each well of the 96-well microtitre plates was checked under an optical microscope for the presence of cytopathic effect in the cell lawn and compared with the negative and positive controls. The virus neutralization titre was defined as the antibody dilution by means of which 50% of the wells were protected against a virus-induced cytopathic effect. The Spearman-K€ arber formula was used to calculate the virus neutralization titre of each sample.

The data were pre-processed (quality control, background subtraction, outliers and false positives detection and removal) and normalized as previously described. 28, 29 Differential recognition was estimated by using Significance Analysis for Microarrays, 35 a non-parametric penalized t-test for microarrays. Exclusive recognition was performed by fixing a threshold for detection (corresponding to the average response in the negative controls + 2 9 standard deviation) and by counting the number of detection hits among cases for the peptides that have a level of recognition always below this value in all the controls. 16 The number of hits is then reported together with the average recognition. All the procedures were performed by using in-house-made R scripts, and packages from the project BIOCONDUCTOR(www.bioconductor.org). 36

The differential epitope-serum IgG recognition patterns segregate into clusters based on pandemic influenza infection and Pandemrix â vaccination

Serum from each individual was tested for IgG recognition using the influenza peptide microarray platform. Serum IgG epitope reactivity from 19 individuals before and after H1N1 infection was compared with serum reactivity (sex-and age-matched) in individuals before and after Pandemrix â vaccination from the same prospective study cohort. Peptides that were recognized differentially (P < 0Á001) in both groups, flu infection versus vaccination (significance analysis of microarrays method 35 ), were identified and represented as fold change (Table 2 and Fig. 2 ). Data are presented as the number of times a particular epitope in the group that experienced H1N1 infection is recognized compared with the vaccination group (below onefold change indicates a higher response in the vaccination group).

The epitope-serum IgG recognition patterns segregate into clusters based on the group, i.e. individuals who later contracted a flu infection versus the group who received vaccination (see Fig. 2 ). The prospective study design allowed the characterization of serum reactivity before vaccination as well as before pandemic H1N1 infection. We identified a cluster of 262 epitopes that were differentially recognized pre-vaccination/infection and a cluster of 250 epitopes differentially recognized post-vaccination/infection (represented in heat maps Fig. 2 ).

Before the flu season onset, 13 peptide epitopes were differentially recognized in the group who later experienced the H1N1 infection based on their strong serum recognition pattern (as defined by fluorescence intensity). Only two of these 13 epitopes from the 2009 pandemic flu strain were recognized, i.e. polymerase PA (GRDRIMAWTVVNSIC) and neuraminidase (NFSIKQDIVGINEWS). This was in contrast to the serum reactivity pattern from individuals who chose to be vaccinated, in whom a total of 17 epitopes were differentially recognized, 10 of the 17 epitopes from the pandemic strain (six from polymerase PA, two from matrix1, one from polymerase PB1 and one epitope from HA VE-PGDKITFEATGNL) (exhaustive list in Table 2 ).

After the flu season, 14 epitopes segregated best the vaccinated versus flu-infected individuals (see exhaustive list in Table 3 Table S1 and Table  S2 ). This contrasted with serum from vaccinated individuals, which exhibited serum IgG also to Cb but to the epitope 76-90 amino acids from the H1 HA including GWLLGNPECDLLLTA from Influenza A virus [A/South Carolina/1/1918(H1N1)] (Spanish flu) (list in the Supporting information, Tables S1 and S2).

A novel epitope on the antigenic site of the pandemic flu HA is exclusively recognized in serum from vaccinated individuals

Exclusive recognition analysis was performed, i.e. whether epitopes are recognized strongly and exclusively in one group (flu infection) and never or always below a set cut-off in another group (flu vaccination) or vice versa (Table 4) . We identified an epitope VEPGDKITFEATGNL from the pandemic flu HA that was exclusively recognized in serum from vaccinated individuals before the flu season (16/19 individuals) . This was also found to be true for the post-flu (Fig. 3) .

As the VEPGDKITFEATGNL epitope from the pandemic H1 (251-265 amino acids) was exclusively recognized in serum from control individuals, both before and after vaccination, we tested whether a polyclonal (rabbit), peptide-affinity purified mono-specific antibody could neutralize the virus in vitro. Each of the mono-specific affinity-purified antibody preparations (n = 3) showed an H1 neutralizing titre of < 10, except for the hyperimmune sheep serum tested in the assay as a positive control (data not shown), demonstrating that the epitope-specific antibody recognizes, but does not neutralize, A/California/7/2009 flu live virus, with the tests applied in the current report.

The aim of this study was to characterize the serum-IgG epitope recognition profiles in the course of a natural pandemic influenza infection and Pandemrix â vaccination using a high-content influenza peptide microarray. One salient finding is the pre-existing serum IgG to pandemic HA in vaccinated individuals before the onset of the flu season, probably due to past exposures and previous vaccinations (the interviews of the study participants showed that individuals who chose to be vaccinated did so previously, before 2009/2010 and vice versa. 27 ) Not only pre-existing serum IgG, resulting from previous flu vaccinations, but also pre-existing protective antibodies from past exposures to H1 strains 37-40 may contribute to this humoral response. A broader pandemic flu epitope recognition pattern is reflected in 10 shared pandemic influenza epitopes in serum from individuals before the flu season onset, as well as in seven epitopes from pandemic flu internal proteins in serum from individuals who chose to be vaccinated. The biological role of these antibodies, directed to internal proteins, is not clear. Previous reports suggested that non-neutralizing antibodies may decrease morbidity and lead to increased viral clearance through binding to Fc receptors and subsequently to CD8 cells. [41] [42] [43] [44] [45] Conserved influenza internal proteins may therefore help to elicit memory B cells that are longlived 46,47 and contribute to heterosubtypic immunity during antigenic drifts. Cross-protection can be induced by antibodies against the generic N1 that are reactive against the pandemic N1, as described previously for N2 subtypes. 48, 49 Moreover, in the absence of neutralizing HA antibodies, neuraminidase-specific antibodies would be instrumental to mount protective immune responses against the pandemic virus. 49 Of note, we observed in serum from the current cohort an increase in neuraminidase epitope reactivity, but no pandemic H1 epitopes were commonly recognized. This could be related to the fact that we tested reactivity only against linear epitopes, which is a caveat of the chip design used in the current study, and biologically relevant conformational epitopes may have been missed. 23, 24 Antibodies against swine influenza virus were found to neutralize pandemic flu in experimental models. 50, 51 However non-neutralizing antibodies produced against the swine origin H1due to past exposurescould enhance virus fusion and promote infection. 52 Most significantly, the subjects in the current study who experienced H1N1 infection (confirmed with a positive PCR), exhibited increased levels of IgG against SRYSKKFK-PEIAARP from the HA [Influenza A virus (A/Swine/Indiana/P12439/00 (H1N2))], which is highly homologous to the SRYSKKFKPEIAIRP epitope from HA [Influenza A virus (A/California/08/2009(H1N1))] on the HA receptor binding domain. As a single amino acid mutation in the antigenic site is able to generate a new epidemic strain, 53 there is the possibility of 'misdirected reactivity' 54,55 leading to symptomatic flu infection.

The pandemic HA exhibits conservation of most of the epitopes from the antigenic sites Cb, Sa and Sb compared with the HA of the 1918 Spanish flu, yet significant differences have been described in the Ca antigenic site. 31 The IgG serum reactivity in vaccinated individuals to GWLLGNPECDLLLTA on the antigenic site Cb was directed against vestigial esterase domain on the HA1 [Influenza A virus (A/South Carolina/1/1918(H1N1))] (Spanish flu). This epitope GWLLGNPECDLLLTA from the HA of (Spanish flu) was recognized by serum immunoglobulin at both pre-and post-vaccination time-points (see Supporting information, Tables S1 and S2), supporting the notion that IgG to the Spanish flu may be able to induce cross-protection against the 2009 pandemic flu. In addition, serum from these individuals also exhibited IgG reactivity directed against the non-conserved Ca site to VEPGDKITFEATGNL from the 2009 pandemic H1.

Our data show that serum from the individuals that chose to be vaccinated exhibited strong pre-existing IgG reactivity towards pandemic flu epitopes, particularly to the pandemic flu HA epitope VEPGDKITFEATGNL. This reactivity was completely absent from the IgG-epitope recognition repertoire of the flu-infected individuals before and after the flu season. Most likely, this epitope The top two peptide epitopes are strongly recognized in serum of individuals (before/after Pandemrix â vaccination) or always below the cut-off in the sera of individuals (before/after pandemic flu infection). Note that the epitope VEPGDKITFEATGNL (from the pandemic flu) was exclusively recognized in serum from individuals both before and after Pandemrix â vaccination, yet never in serum from individuals who experienced later H1N1 infection. A rabbit mono-specific antibody directed against this epitope was prepared that did not neutralize the pandemic flu in vitro; functional significance of this epitope could not be established. A possible explanation is that a 15mer linear peptide that was used to immunize the rabbits does not resemble the same folding of this epitope within the native protein. However, the antibodies detected in serum from vaccinated individuals against this epitope may activate complement and subsequently contribute to virus neutralization in a biological system. 56, 57 This test was beyond the scope of the study, since epitope-specific complement-activating human reagents were not available. Future experiments will also need to address whether high-avidity antibodies from flu-protected individuals 58, 59 can be identified with the peptide microarray assay and whether the target epitopes could be used for guided vaccine development. Although the current study may be limited because only IgG directed against linear epitopes could be characterized with conformational epitopes being missed, a distinct IgG recognition pattern was identified. These patterns segregated based on H1N1 infection and vaccination and could be clearly linked to a clinically relevant endpoint: flu infection leads to a different array of epitope recognition compared with the flu vaccine. Immune profiling of individuals, protected from infectious pathogens, may help to tailor new vaccine candidates and help to identify clinically relevant markers of immune protection.

Additional Supporting Information may be found in the online version of this article: Table S1 . Differentially recognized epitopes by serum IgG from individuals (n = 19) who later experienced the pandemic flu infection compared with epitopes recognized by the serum IgG of individuals (n = 19) before Pandemrix â vaccination. Table S2 . Differentially recognized epitopes by serum IgG from individuals (n = 19) post pandemic flu infection compared with the epitopes recognized by serum IgG of individuals (n = 19) after Pandemrix â vaccination (≥ 6 months). The values are presented as fold change.

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

Antigenic and genetic characteristics of swineorigin 2009 A(H1N1) influenza viruses circulating in humans

Emergence and pandemic potential of swine-origin H1N1 influenza virus

A novel H1N1 virus causes the first pandemic of the 21st century

The 2009 A(H1N1) Pandemic in Europe. Stockholm: ECDC

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus

Jackson P. Older age and a reduced likelihood of 2009 H1N1 virus infection

In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses

Influenza hemagglutinin and neuraminidase membrane glycoproteins

Immunity to influenza in man

Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosis

Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status

Analysis of the antibody repertoire of lymphoma patients

Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120

Enzyme-linked immunosorbent assay (ELISA)

A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes

Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics

LifeGene -a large prospective populationbased study of global relevance

Markus Maeurer on the LifeGene project

Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 Influenza pandemic

Validation of peptide epitope microarray experiments and extraction of quality data

Identification and testing of control peptides for antigen microarrays

Humoral 'reactome' profiles using peptide microarray chips

Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus

The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure

Jmol: an open-source Java viewer for chemical structures in 3D

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays

Significance analysis of microarrays applied to the ionizing radiation response

Bioconductor: open software development for computational biology and bioinformatics

Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population

Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population

Pre-existing cross-reactive antibodies to avian influenza H5N1 and 2009 pandemic H1N1 in US military personnel

Preexisting immunity to pandemic (H1N1)

A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus

Clonal dissection of the human memory B-cell repertoire following infection and vaccination

Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus

HLA class I molecules consistently present internal influenza epitopes

Influenza basic polymerase 2 peptides are recognized by influenza nucleoprotein-specific cytotoxic T lymphocytes

Duration of humoral immunity to common viral and vaccine antigens

Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance

Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong/68 virus

Association of serum anti-neuraminidase antibody with resistance to influenza in man

Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1

The incidence of neutralizing antibodies for swine influenza virus in the sera of human beings of different ages

Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease

Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation

Immune history shapes specificity of pandemic H1N1 influenza antibody responses

Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution

A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutininspecific antibodies that display very low virus-neutralizing activity in vitro

Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype

Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes

High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza

The authors wish to thank the Swedish Research Council and Karolinska Institute for funding this study. MM conceived, planned and obtained funding for the study, AA, IS, GL and FB performed the experiments. DV, AA and IS analysed the data, AA and MM wrote the first draft, HW and EM contributed in the form of ideological inputs.

The authors declare no conflict of interest.

Swedish Research Council (VR) and Karolinska Institutet.